Skip to main content

Table 4 90-day mortality in patients with coronavirus disease 2019 identified by Cox proportional hazards regression model, considering neuromuscular blocking agents (NMBAs) treatment as at least 2 days of continuous use of NMBAs and up to 3 days, within 48 h from commencement of IMV

From: Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

 

Propensity score-matched cohorta

(N = 420)

Variable

Adjusted hazard ratio for 90-day mortality^

95% CI

p value

NMBA treatment

1.07

0.72, 1.61

0.729

NMBA treatment and corticosteroids

1.09

0.39, 3.05

0.872

NMBA treatment per PaO2/FiO2 Strata within 24 h from Commencement of IMV

   

 < 100

0.70

0.28, 1.74

0.445

100–149

(Reference)

–

–

  1. aPost-propensity score matching, also adjusting for smoking, use of antibiotics, antivirals, corticosteroids, renal replacement therapy, ECMO, and prone positioning. N = 420, due to equally sized cohorts post-propensity score matching
  2. IMV, invasive mechanical ventilation; NMBA, neuromuscular blocking agents; PaO2/FiO2, ratio between arterial partial pressure of oxygen and inspiratory fraction of oxygen
Back to article page

Critical Care

ISSN: 1364-8535